𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Recombinant interferon α-2b in the treatment of polycythemia vera

✍ Scribed by Renato Cimino; Vincenzo Rametta; Carmela Matera; Giuseppina Mele; Vincenzo Mettivier; Felicetto Ferrara

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
240 KB
Volume
44
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Role of interferon alpha-2a in the treat
Role of interferon alpha-2a in the treatment of polycythemia vera
✍ Paolo Foa; Paolo Massaro; Sonia Ribera; Alessandra Lurlo; Carmen Mezzanotte; Dan 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 210 KB 👁 2 views

We studied the effects of recombinant interferon alpha-2a (IFN-alpha) in 36 patients with polycythemia Vera (PV) previously treated with phlebotomy and/or conventional cytostatic agents. In each patient, after at least 2 months of discontinuation of any cytotoxic therapy, the hematocrit (Hmt) was fi

Relief of intractable pruritus in polycy
Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa
✍ Dr. Carlo Finelli; Luigi Gugliotta; Barbara Gamberi; Nicola Vianelli; Giuseppe V 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB 👁 2 views

Following reports that recombinant interferon alfa (rlFNu), besides inducing clinical and hematologic remission in polycythemia Vera (PV), can also resolve intractable pruritus, we used rlFNu to treat 13 PV patients complaining of severe pruritus refractory to conventional treatment (venesection and

Polycythemia vera treated with recombina
Polycythemia vera treated with recombinant interferon-alpha 2a: Evidence of a selective effect on the malignant clone
✍ Massaro, Paolo; Foa, Paolo; Pomati, Mauro; LaTargia, Maria Luisa; Iurlo, Alessan 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 15 KB 👁 2 views

We periodically analyzed bone-marrow cytogenetic features in 8 patients belonging to a series of 38 subjects with polycythemia vera (PV), all treated with recombinant interferonalpha 2a (rIFN-alpha) at a weekly dose of 9,000,000 IU. Six out of these 8 patients never showed any chromosome alterations

Treatment of advanced medullary thyroid
Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon α-2b and octreotide
✍ Giovanni Lupoli; Edvige Cascone; Francesco Arlotta; Giovanni Vitale; Luigi Celen 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 436 KB 👁 2 views

## BACKGROUND. The medical treatment of advanced medullary thyroid carcinoma (MTC) is still questionable. Results of chemotherapy are disappointing with almost no curative responses, few partial responses, and many side-effects. A recent report has suggested the activity of combination recombinant

α-2a interferon therapy and antibody for
α-2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis
✍ E. Törnebohm-Roche; M. Merup; D. Lockner; Dr. C. Paul 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 479 KB 👁 1 views

In ten patients with essential thrombocythemia and polycythemia Vera with thrombocytosis we have investigated the therapeutic effect of recombinant a-2a interferon (Roceron-A@) given subcutaneously in a maintenance dosage of 3 million units three times weekly. The aim was to normalize the platelet